|
1) Matsumoto T, Iida M, Matsui T, et al. Non-specific multiple ulcers of the small intestine unrelated to non-steroidal anti-inflammatory drugs. J Clin Pathol. 2004; 57: 1145-50
|
|
|
|
2) Matsumoto T, Nakamura S, Esaki M, et al. Endoscopic features of chronic nonspecific multiple ulcers of the small intestine: comparison with nonsteroidal anti-inflammatory drug-induced enteropathy. Dig Dis Sci. 2006; 51: 1357-63
|
|
|
|
|
|
3) 塩川優一, 延永 正, 斎藤輝信, 他. 非ステロイド性抗炎症剤による上部消化管傷害に関する疫学調査. リウマチ. 1991; 31: 96-111
|
|
|
|
|
4) Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340: 1888-99
|
|
|
|
|
|
5) 平石秀幸, 寺野 彰. 胃粘膜病変とフリーラジカル. 日消誌. 1995; 92: 1817-24
|
|
|
|
|
|
6) NSAID潰瘍. EBMに基づく胃潰瘍診療ガイドライン(菅野健太郎, 編) 第2版. 東京: じほう. 2007; p. 101-12
|
|
|
|
|
|
7) Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med. 2006; 38: 415-28
|
|
|
|
|
|
8) Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343: 1520-8
|
|
|
|
|
|
9) Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284: 1247-55
|
|
|
|
|
|
10) Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006; 119: 255-66
|
|
|
|
|
|
11) Laine L, Curtis SP, Cryer B, et al. MEDAL Steering Committee Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007; 369: 465-73
|
|
|
|
|
|
12) Cannon CP, Curtis SP, FitzGerald GA, et al. MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368: 1771-81
|
|
|
|
|
|
13) Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006; 101: 701-10
|
|
|
|
|
|
14) Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007; 369: 1621-6
|
|
|
|
|
|
15) Yamao J, Kikuchi E, Matsumoto M, et al. Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE-famotidine or rebamipide in comparison by endoscopy). J Gastroenterol. 2006; 41: 1178-85
|
|
|
|
|
|
16) Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002; 359: 14-22
|
|
|
|
|
|
17) Vergara M, Catalan M, Gisbert JP, et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005; 21: 1411-8
|
|
|
|
|
|
18) Sakamoto C, Sugano K, Ota S, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006; 62: 765-72
|
|
|
|
|
|
19) Lanas A, Perez-Aisa MA, Feu F, et al. Investigators of the Asociacion Espanola de Gastroenterologia (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005; 100: 1685-93
|
|
|
|
|
|
20) Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003; 124: 288-92
|
|
|
|
|
|
21) Graham DY, Opekun AR, Willingham FF, et al. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005; 3: 55-9
|
|
|
|
|
|
22) Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005; 3: 133-41
|
|
|
|
|
|
23) Leung WK, Bjarnason I, Wong VW, et al. Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet. 2007; 369: 614
|
|
|
|
|
|
24) Scarpignato C. Nonsteroidal anti-inflammatory drugs: how do they damage gastroduodenal mucosa？ Dig Dis. 1995; 13(Suppl 1): 9-39
|
|
|
|
|
|
25) Watanabe T, Higuchi K, Kobata A, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is toll-like receptor 4 dependent. Gut. 2007 [Epub ahead of print]
|
|
|
|
|
|
26) Shimizu K, Koga H, Iida M, et al. Microcirculatory changes in experimental mesenteric longitudinal ulcers of the small intestine in rats. Dig Dis Sci. 2007 [Epub ahead of print]
|
|
|
|
|